Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 24462322)

1.

Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis.

Maillard MH, Bortolotti M, Vader JP, Mottet C, Schoepfer A, Gonvers JJ, Burnand B, Froehlich F, Michetti P, Pittet V; Swiss IBD Cohort Study Group.

J Crohns Colitis. 2014 Aug;8(8):825-34. doi: 10.1016/j.crohns.2013.12.026. Epub 2014 Jan 22.

PMID:
24462322
2.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
3.

The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all.

Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA.

Clin Gastroenterol Hepatol. 2010 Aug;8(8):655-9. doi: 10.1016/j.cgh.2010.04.023. Epub 2010 May 6.

PMID:
20451665
4.

Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.

Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.

Dig Liver Dis. 2005 Jun;37(6):407-17. Review.

PMID:
15893279
6.

Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit.

Lynch RW, Lowe D, Protheroe A, Driscoll R, Rhodes JM, Arnott ID.

Aliment Pharmacol Ther. 2013 Oct;38(8):935-45. doi: 10.1111/apt.12473. Epub 2013 Sep 4.

PMID:
24004000
7.

Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Rutgeerts P; PURSUIT-Maintenance Study Group.

Gastroenterology. 2014 Jan;146(1):96-109.e1. doi: 10.1053/j.gastro.2013.06.010. Epub 2013 Jun 14.

PMID:
23770005
8.

Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy.

Farkas K, Lakatos PL, Nagy F, Szepes Z, Miheller P, Papp M, Palatka K, Bálint A, Bor R, Wittmann T, Molnár T.

Scand J Gastroenterol. 2013 Dec;48(12):1394-8. doi: 10.3109/00365521.2013.845906. Epub 2013 Oct 16.

PMID:
24131338
9.

Update on the management of ulcerative colitis.

Taba Taba Vakili S, Taher M, Ebrahimi Daryani N.

Acta Med Iran. 2012;50(6):363-72. Review.

10.

Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis.

McDermott E, Murphy S, Keegan D, O'Donoghue D, Mulcahy H, Doherty G.

J Crohns Colitis. 2013 Mar;7(2):150-3. doi: 10.1016/j.crohns.2012.03.016. Epub 2012 Apr 18.

PMID:
22520592
11.

Topical therapy is underused in patients with ulcerative colitis.

Seibold F, Fournier N, Beglinger C, Mottet C, Pittet V, Rogler G; Swiss IBD cohort study group.

J Crohns Colitis. 2014 Jan;8(1):56-63. doi: 10.1016/j.crohns.2013.03.005. Epub 2013 Apr 6.

PMID:
23566922
12.

Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients.

Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M.

Dig Liver Dis. 2002 Sep;34(9):626-30.

PMID:
12405248
13.

Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.

Molander P, Färkkilä M, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J, Arkkila P, Nieminen U, Kuisma J, Punkkinen J, Kolho KL, Mustonen H, Sipponen T.

Inflamm Bowel Dis. 2014 Jun;20(6):1021-8. doi: 10.1097/MIB.0000000000000052.

PMID:
24798636
14.

The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.

Afzali A, Wheat CL, Hu JK, Olerud JE, Lee SD.

J Crohns Colitis. 2014 Jun;8(6):480-8. doi: 10.1016/j.crohns.2013.10.013. Epub 2013 Nov 21.

PMID:
24268978
15.

Cyclosporine A for induction of remission in severe ulcerative colitis.

Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004277. Review.

PMID:
15674937
16.

Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease.

Rubin DT, Mody R, Davis KL, Wang CC.

Aliment Pharmacol Ther. 2014 May;39(10):1143-55. doi: 10.1111/apt.12727. Epub 2014 Apr 3.

PMID:
24697826
17.

Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort.

Gies N, Kroeker KI, Wong K, Fedorak RN.

Aliment Pharmacol Ther. 2010 Aug;32(4):522-8. doi: 10.1111/j.1365-2036.2010.04380.x. Epub 2010 May 25.

PMID:
20500733
18.

Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents.

Molander P, af Björkesten CG, Mustonen H, Haapamäki J, Vauhkonen M, Kolho KL, Färkkilä M, Sipponen T.

Inflamm Bowel Dis. 2012 Nov;18(11):2011-7. doi: 10.1002/ibd.22863. Epub 2012 Jan 4.

PMID:
22223566
19.

Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.

Subramaniam K, Richardson A, Dodd J, Platten J, Shadbolt B, Pavli P.

Intern Med J. 2014 May;44(5):464-70. doi: 10.1111/imj.12397.

PMID:
24612209
20.

Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.

Thukral C, Cheifetz A, Peppercorn MA.

Drugs. 2006;66(16):2059-65. Review.

PMID:
17112300
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk